School Of Medicine, University of Limerick, Limerick, Ireland
Medical Oncology, University Hospital Limerick, Limerick, Ireland.
BMJ Open. 2022 May 2;12(5):e061397. doi: 10.1136/bmjopen-2022-061397.
Colorectal cancer remains the second leading cause of cancer-related death in 60-79 years old and the third leading cause of death in patients aged 80 and above. Rectal cancer accounts for approximately a third of colorectal cancer diagnoses. The current standard of care for managing locally advanced rectal cancer involves a multimodal combined approach with neoadjuvant treatment, surgery with total mesorectal excision and adjuvant chemotherapy. Neoadjuvant treatment can be in the form of short-course radiotherapy, long-course concurrent radiotherapy with chemotherapy or total neoadjuvant chemotherapy with concurrent chemoradiotherapy followed by chemotherapy. This scoping aims to assess the toxicity and outcome of the different neoadjuvant treatment modalities in elderly patients.
We will use Arksey and O'Malley's five scoping review methodology framework stages. Searches will be conducted in Ovid Medline, Embase, Cochrane database and CINAHL. In addition, the researcher will hand search for all registered trials, using a combination of terms such as "locally advanced rectal cancer", "neoadjuvant treatment", and "elderly patients." Two independent reviewers will screen titles and abstracts and then full text based on predefined inclusion and exclusion criteria. Publications will be extracted using a customised data extraction tool to include study characteristics, research topics, exposures and outcomes.
Ethics approval is not required as the data will be collected from the existing literature. The findings of this study will help with future clinical research on the topic. We will publish the findings of this review in a peer-reviewed journal and present them at academic conferences targeting geriatric oncology service providers.
在 60-79 岁人群中，结直肠癌仍然是癌症相关死亡的第二大主要原因，在 80 岁及以上人群中是第三大主要死因。直肠癌约占结直肠癌诊断的三分之一。目前，局部晚期直肠癌的治疗标准包括新辅助治疗、全直肠系膜切除术联合手术和辅助化疗的多模态联合治疗。新辅助治疗可以采用短程放疗、长程同期放化疗或总新辅助化疗联合同期放化疗加化疗。本研究旨在评估不同新辅助治疗方式在老年患者中的毒性和结局。
我们将使用 Arksey 和 O'Malley 的五个范围综述方法框架阶段。将在 Ovid Medline、Embase、Cochrane 数据库和 CINAHL 中进行搜索。此外，研究人员将使用“局部晚期直肠癌”、“新辅助治疗”和“老年患者”等组合术语对手头搜索的所有注册试验进行搜索。两名独立的评审员将根据预先设定的纳入和排除标准筛选标题和摘要，然后是全文。将使用定制的数据提取工具提取出版物，以包括研究特征、研究主题、暴露和结局。
不需要伦理批准，因为数据将从现有文献中收集。本研究的结果将有助于未来关于该主题的临床研究。我们将在同行评议的期刊上发表本综述的研究结果，并在面向老年肿瘤学服务提供者的学术会议上展示。
